Thursday, June 11

Browsing: DESCART

Support

Key Perspectives on Real World CAR-T Use in R/R LBCL (DESCAR-T & REALYSA Registries)

By NewsCancerFebruary 21, 20260

Panelists discuss how to optimally integrate CAR T-cell therapy into second-line treatment for diffuse large B-cell lymphoma through a competitive,…

Treatments

Examining CAR-T Outcomes in 2L LBCL Treatment (Axi-cel & Liso-cel, DESCAR-T Registry)

By NewsCancerFebruary 21, 20260

Panelists analyze comparative real-world data from the French DESCAR-T registry evaluating axicabtageneciloleucel and lisocabtagenemaraleucel in second-line relapsed/refractory LBCL. Faculty consider…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Scientists shut down cancer DNA repair to overcome drug resistance

The future is not always uniform: rethinking radiotherapy through spatial fractionation

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

Browsing: DESCART

Key Perspectives on Real World CAR-T Use in R/R LBCL (DESCAR-T & REALYSA Registries)

Examining CAR-T Outcomes in 2L LBCL Treatment (Axi-cel & Liso-cel, DESCAR-T Registry)

Scientists shut down cancer DNA repair to overcome drug resistance

The future is not always uniform: rethinking radiotherapy through spatial fractionation

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

76 Real-World Safety of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Insights From US Community Oncology Practices

Scientists shut down cancer DNA repair to overcome drug resistance

The future is not always uniform: rethinking radiotherapy through spatial fractionation

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

76 Real-World Safety of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Insights From US Community Oncology Practices

Latest Post

Scientists shut down cancer DNA repair to overcome drug resistance

The future is not always uniform: rethinking radiotherapy through spatial fractionation

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

Subscribe to Updates

What's Hot

Browsing: DESCART